HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nascimbeni, A. C. Articles by Angelini, C. Search for Related Content PubMed PubMed Citation Articles by Nascimbeni, A. C. Articles by Angelini, C.

Molecular pathology and enzyme processing in various phenotypes of acid maltase deficiency

From the Neuromuscular Centre, Department of Neurosciences, University of Padova; and Venetian Institute of Molecular Medicine, Padova, Italy.

Address correspondence and reprint requests to Dr. M. Fanin, Venetian Institute of Molecular Medicine, via Giuseppe Orus 2, 35129 Padova, Italy marina.fanin{at}unipd.it

Objectives: To examine at molecular, biochemical, and muscle pathology level the striking clinical heterogeneity resulting from acid -glucosidase deficiency.

Methods: We investigated 23 patients with infantile-onset or late-onset glycogen storage disease type II by enzyme activity, protein expression by immunoblotting, GAA gene mutations, and muscle pathology including immunolabeling for Golgi and sarcolemmal proteins.

Results: The enzyme activity was absent or minimal in infantile-onset cases and variably reduced in late-onset patients. Genotype-phenotype correlation (seven novel mutations were found) showed that most late-onset patients had the heterozygous IVS1 leaky splicing mutation (one patient was homozygous), but the course of the disease was often difficult to predict on the basis of the mutations alone. All patients showed an abnormal pattern of enzyme protein processing, with increased amounts of the inactive forms and very low or absent amounts of the mature forms. The molecular weight of the mature and the intermediate forms appeared higher in patients’ samples than in the control muscle. We observed a Golgi proliferation in muscle fibers possibly caused by the retention of inactive forms of enzyme protein that cannot be correctly targeted from Golgi to lysosomes. The vacuolar membranes expressed sarcolemmal proteins in late-onset but not in infantile-onset patients, suggesting an extensive autophagy and vacuolar membrane remodeling in late-onset patients.

Conclusions: The different protein molecular weight between patients and controls could be due to an excessive sialylation of mutant enzyme: this might be possibly caused by a delayed transport and longer transit of the inactive proteins in the Golgi apparatus.

Abbreviations: ER = endoplasmic reticulum; ERT = enzyme replacement therapy; GSDII = glycogen storage disease type II; H-E = hematoxylin-eosin; LAMP-1 = lysosomal-associated-membrane-protein-1; M6P = mannose-6-phosphate; PBS = phosphate-buffered saline.

Funded by grants from Telethon-Italy (GTF05003), the Eurobiobank network (QLRT2001-027769), and the Italian Ministry for University and Research (COFIN 2006/062912).

Disclosure: The authors report no conflicts of interest.

Received July 3, 2007. Accepted in final form August 20, 2007.

This article has been cited by other articles:

				C. Angelini, C. Semplicini, P. Tonin, M. Filosto, E. Pegoraro, G. Soraru, and M. Fanin Progress in enzyme replacement therapy in glycogen storage disease type II Therapeutic Advances in Neurological Disorders, May 1, 2009; 2(3): 143 - 153. [Abstract] [PDF]

				C. Angelini Recent advances and current clinical perspectives in the diagnosis and treatment of glycogenosis type II Neurology, December 2, 2008; 71(23_suppl_2): S1 - S2. [Full Text] [PDF]